We recently published a list of Was Jim Cramer Right About These 23 Stocks?. In this article, we are going to take a look at ...

As alleged, Fluence Energy misrepresented the strength of its competitive position, sales pipeline, and backlog of orders. In reality, Fluence Energy concealed declines in its sales and earnings ...

StockNews.com upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) from a hold rating to a buy rating ...

The general mood among these heavyweight investors is divided, with 44% leaning bullish and 33% bearish. Among these notable options, 5 are puts, totaling $256,004, and 4 are calls, amounting to ...

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept ...

In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with ...

GCC Erectile Dysfunction Drugs Market – Industry Trends & Forecast Report, 2029 ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Federal Circuit Ruling Potentially Upends Orange Book Patent Listing Requirements, Expert Analysis Reveals This ruling marks a pivotal moment in Hatch-Waxman practice, potentially altering how ...

The University of Wisconsin-Madison College Democrats and College Republicans are campaigning on abortion rights and public ...